This strategy targets 7‐dehydrocholesterol reductase (DHCR7) in GSM using a degradable NR carrier to inhibit cholesterol biosynthesis and reduce the cholesterol supply from GSM to tumor cells, thereby limiting tumor cell survival and proliferation (Figure 2). The gene discussed is DHCR7; the disease is neoplasm.